Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer

DOI Full Paper Access

13

Citations

21

References

2019

Year

Elisabeth I. Heath, Lance K. Heilbrun, Heather D. Mannuel, Glenn Liu, Primo Lara, J. Paul Monk, Thomas W. Flaig, Amado J. Zurita, Philip C. Mack, Ulka N. Vaishampayan,

Abstract

Combining cediranib with docetaxel + prednisone failed to demonstrate superior efficacy, compared with docetaxel + prednisone, and added toxicity. Our data do not support pursuing the combination further in patients with mCRPC.

References

	Year	Citations

Page 1